drugset
drugset / Trial / NCT00374803

Study of Myfortic in Combination With Tacrolimus and Thymoglobulin in Early Corticosteroid Withdrawal

NCT00374803 ↗

Phase 4 Completed 45 enrolled University of Cincinnati Novartis · collab
RandomizedParallel-groupOpen-labelTreatment

Summary

To determine the safety and efficacy of a new formulation of Myfortic in combination with tacrolimus and thymoglobulin.

Timeline

Start
2006-04
Primary completion
2008-01
Completion
2008-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Mycophenolic Acid (Myfortic) Unknown 720 mg —

Indications

end stage renal failure